Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57624 | 1.00 | KMT2A (0.43) | KMT2AMEN1TUBB1POLBLMNA | |
| SCHEMBL17734005 | 0.92 | TUBB1 (0.46) | KMT2AMEN1TUBB1FKBP1A | |
| SCHEMBL13681991 | 0.92 | TUBB1 (0.46) | KMT2AMEN1TUBB1FKBP1A | |
| SCHEMBL58625 | 0.92 | TUBB1 (0.46) | KMT2AMEN1TUBB1FKBP1A | |
| SCHEMBL88749 | 0.92 | TUBB1 (0.46) | KMT2AMEN1TUBB1FKBP1A | |
| SCHEMBL22283984 | 0.91 | TUBB1 (0.47) | KMT2AMEN1TUBB1FKBP1A | |
| SCHEMBL22283983 | 0.91 | TUBB1 (0.47) | KMT2AMEN1TUBB1FKBP1A | |
| SCHEMBL22069909 | 0.91 | TUBB1 (0.47) | KMT2AMEN1TUBB1FKBP1A | |
| SCHEMBL28381670 | 0.91 | TUBB1 (0.47) | KMT2AMEN1TUBB1FKBP1A | |
| SCHEMBL28380575 | 0.91 | TUBB1 (0.47) | KMT2AMEN1TUBB1FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312419-B2 | Hemiasterlin derivative having cysteine residue | Sumitomo Pharma Co., Ltd. (JP) | 2025-05-27 | — | — | US | disclosed |
| CN-113412271-B | Having cysteine residues Hamiltelin derivatives of (C) | 住友制药株式会社 | 2024-10-22 | — | — | CN | disclosed |
| EP-3666787-B9 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-111032676-B | Antibody drug complexes comprising hamiltin derivatives | 住友制药株式会社 | 2024-08-23 | — | — | CN | disclosed |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-22 | — | — | US | disclosed |
| EP-3666787-B1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-02-21 | — | — | EP | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SHBG, CYP11A1, CYP11B1 | KMT2A 3110/4885MEN1 579/4885TUBB1 1472/4885 |
| US-12312419-B2 | Hemiasterlin derivative having cysteine residue | SHBG, CYP11A1, CYP11B1 | KMT2A 3110/4885MEN1 579/4885TUBB1 1472/4885 |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | KMT2A 3692/4885MEN1 251/4885TUBB1 1330/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | KMT2A 2112/4885MEN1 707/4885TUBB1 624/4885 |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | DHCR7, HSD17B7, HCCS | KMT2A 3297/4885MEN1 274/4885TUBB1 1668/4885 |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | KMT2A 2112/4885MEN1 707/4885TUBB1 624/4885 |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | DHCR7, CYP46A1, NR1H2 | KMT2A 3889/4885MEN1 173/4885TUBB1 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.